AKTX - Akari Therapeutics PLC
Akari Therapeutics PLC Logo

AKTX - Akari Therapeutics PLC

https://www.akaritx.com
Momentum: Bearish
Recent News
Powered by Alpha Vantage
AI Tools
Key Metrics
Trend: Downtrend
Source: Snapshot

Akari Therapeutics, Plc, a clinical-stage biopharmaceutical company, focuses on the development and commercialization of treatments for autoinflammatory diseases that involve complement and leukotriene pathways. The company is headquartered in London, the United Kingdom.

52W High
$3.85
52W Low
$0.57
MA Status:
50D: Below 200D: Below
Beta (~1 neutral, <0.9 lower risk)
0.27
Valuation
As of 2025-06-30 (Overview)
Trailing P/E (<15 better)
N/A
Forward P/E (<15 better)
N/A
EV/EBITDA (<8 favorable)
-0.06
EV/Revenue (<3 favorable)
N/A
P/S (TTM) (<3 favorable)
N/A
P/B (<3 favorable)
1.04
Ownership
Retail‑heavy
Source: Overview
Insiders (1–5% typical)
34.29%
Institutions (25–75% balanced)
1.73%
Shares Outstanding
32,614,700
Float
11,199,899,000
Dividend Yield (2–6% sweet spot)
N/A
Ex‑Dividend Date
N/A
Income & Growth
Profitability: Weak
As of 2025-06-30 (Overview)
Revenue (TTM)
0
Gross Profit (TTM)
0
EPS (TTM)
0.00
Profit Margin (>10% good)
N/A
Operating Margin (TTM) (higher better)
N/A
ROE (TTM) (>15% strong)
-1.12%
EPS YoY (Quarterly) (>10% good)
N/A
Revenue YoY (Quarterly) (>8% good)
N/A
Momentum
Bearish momentum
Value
-0.0729
Previous
-0.0741
Trend
Rising
Signal Cross
No cross
As of
Sep. 11, 2025